Un diagnostic favorable pour un re-rating du titre- ACHAT - OC 65€
Nous initions la couverture avec une recommandation ACHAT assortie d’un objectif de 65€. Les leviers de croissance du groupe nous paraissent intacts et nous apprécions la stratégie visant à pénétrer de nouveaux pans de marché (biologie moléculaire et petits/mégas labs). En revanche, malgré certains leviers sur la rentabilité, nous restons prudents sur la faculté du groupe à renforcer sa marge après 2018. Diasorin présente une décote par rapport à ses pairs qui s’est injustement creusée depuis le S1.Diasorin is engaged in the market for in vitro diagnostics. Co. is developing, producing and commercializing diagnostic tests that are designed for hospital and private testing laboratories for use in different clinical areas in the market of immunodiagnostics and molecular diagnostics. In the immunodiagnostics market segment, Co. develops, produces and markets immunoreagent kits based on three different detection techniques. In the molecular diagnostics segment, Co. supplies end laboratories with an automated solution to perform the three steps required for the final diagnostic result.
Since 2006, Invest Securities has become one of the leading players in investment services for funds and managers, to whom we offer a global and personalised service. Our track record differentiates us and proves our leadership in numerous promising sectors like property and growth companies.
Consisting of 13 different profiles (pharmacist, engineer, financier, etc), the DNA of our financial analysis office is value added and sector expertise. Through daily monitoring and detailed analyses of companies and sectors, we seek to provide a differentiating vision of our 120 stocks followed. Our ideas are circulated every day to nearly 1,000 professionals.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.